$NPHC "Pediatric Multiple Sclerosis is a pressing and unmet medical need," stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. "These children have no therapeutic options that have been proven to be safe and effective for their disease. They must rely on off-label use of adult MS drugs," he continued. "We have been laying the groundwork to move into sanctioned trials ever since we received Orphan Designation for RPI-78M. Standardizing and scaling up drug production with BSF is the next logical step," he concluded.

https://finance.yahoo.com/news/nutra-pharma-a...00318.html